Lynparza (olaparib) doesn’t produce results you can feel or measure at home. It’s a maintenance therapy, meaning it works quietly in the background to keep cancer from coming back or progressing. There’s no single moment when it “kicks in,” but the drug begins interfering with cancer cell repair mechanisms within hours of your first dose. The meaningful question is how long it takes to see clinical benefit, and that’s measured in months, not days or weeks.
How Lynparza Works at the Cellular Level
Lynparza belongs to a class of drugs called PARP inhibitors. PARP is a protein your cells rely on to fix damaged DNA. Every cell in your body sustains thousands of DNA breaks daily, and PARP is one of the key repair tools. When Lynparza blocks PARP, those breaks accumulate.
Healthy cells can usually work around this because they have backup repair systems. But cancer cells with certain genetic mutations, most notably BRCA1 or BRCA2, have already lost one of their major backup pathways. Blocking PARP on top of that existing deficiency leaves the cancer cell with no viable way to fix its DNA. The damage piles up until the cell can no longer divide and dies. This concept is called synthetic lethality: neither defect alone is fatal to the cell, but together they are.
This process starts quickly at the molecular level. Lab studies show measurable DNA damage accumulating in vulnerable cells within 48 to 72 hours of exposure. But translating that cellular damage into a detectable change on a scan or blood test takes considerably longer, because billions of cancer cells need to be affected before the overall tumor burden shifts.
What Clinical Trials Show About Timing
Lynparza is most commonly used as maintenance therapy after chemotherapy has already shrunk or stabilized the cancer. Its job is to extend the time before the disease progresses. That means its benefit is measured not by tumor shrinkage but by how many months pass before cancer returns.
The landmark SOLO-1 trial studied Lynparza as maintenance therapy in women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Patients who took Lynparza after responding to chemotherapy had a median progression-free survival of 56 months, compared to 13.8 months for those on placebo. That’s roughly four years of additional time before disease progression, a dramatic difference that confirmed the drug’s long-term effectiveness.
These numbers reflect population-level averages. Some patients benefit for much longer, others for a shorter period. But the key takeaway is that Lynparza’s clinical benefit unfolds over months and years. You won’t feel a difference after your first week, and your oncologist won’t expect to see scan changes for several months.
What to Expect in the First Few Months
Most oncologists schedule the first imaging scan to assess Lynparza’s effectiveness around 8 to 12 weeks after starting treatment. Before that point, there typically isn’t enough data to judge whether the drug is doing its job. Blood tests, including tumor markers like CA-125 for ovarian cancer, may be checked more frequently but can fluctuate early on without indicating a problem.
During these early weeks, the more noticeable experience is managing side effects rather than seeing evidence of benefit. Common side effects include nausea, fatigue, and changes in blood counts. Nausea tends to be most pronounced in the first few weeks and often improves with time or anti-nausea medication. Fatigue can persist longer. Your medical team will monitor your blood work regularly because Lynparza can lower red blood cells, white blood cells, and platelets.
The standard dose is 300 mg taken twice daily, with or without food. If side effects become difficult to manage, your oncologist may reduce the dose to 250 mg twice daily, or further to 200 mg twice daily. These reductions can make the drug more tolerable without necessarily compromising its effectiveness.
How You’ll Know It’s Working
Because Lynparza is a maintenance therapy, “working” often looks like nothing happening. No new tumors on your scan, stable or declining tumor markers, no new symptoms. That absence of change is the goal. It can feel anticlimactic compared to chemotherapy, where you might watch a tumor shrink in real time, but stable disease on a PARP inhibitor is a genuine success.
Your oncologist will track your response through periodic imaging (typically every 3 to 4 months) and blood work. If scans remain stable and your markers hold steady, the drug is doing what it’s designed to do. Some patients stay on Lynparza for two years as a defined course of maintenance therapy, while others continue for longer depending on their specific cancer type and treatment plan.
Factors That Affect How Well It Works
The single biggest predictor of Lynparza’s effectiveness is your tumor’s genetic profile. Cancers with BRCA1 or BRCA2 mutations respond most strongly because those mutations knock out the backup DNA repair system that cells would normally use to survive PARP inhibition. Tumors with other DNA repair deficiencies can also respond, but typically not as dramatically.
How well your cancer responded to prior chemotherapy also matters. Patients who achieved a complete or strong partial response to platinum-based chemotherapy before starting Lynparza tend to have longer progression-free survival on the drug. This makes sense biologically: if chemotherapy already reduced the cancer to a minimal level, Lynparza has fewer remaining cells to control.
Certain medications can interfere with how your body processes Lynparza. Drugs that strongly inhibit a liver enzyme called CYP3A can increase Lynparza levels in your blood, requiring a dose reduction to avoid excess side effects. Kidney function also plays a role. Patients with moderate kidney impairment need a lower dose because the drug clears more slowly from their system. Your oncologist will account for both of these factors when setting your dose.
When Lynparza Stops Working
Cancer cells can eventually develop resistance to PARP inhibitors by restoring their DNA repair capabilities through new mutations. When this happens, scans will show disease progression, and your oncologist will discuss next steps. The timeline varies widely. Some patients progress within months, while others maintain stable disease for years. In the SOLO-1 trial, a significant proportion of patients on Lynparza remained progression-free beyond five years.
If you notice new or worsening symptoms between scheduled scans, such as increasing pain, unexplained weight loss, or new lumps, let your oncologist know. These could signal progression that warrants earlier imaging. But day-to-day fluctuations in how you feel, especially fatigue and digestive symptoms, are more likely side effects of the drug itself than signs that it’s stopped working.